| Original language | English (US) |
|---|---|
| Pages (from-to) | 1380-1381 |
| Number of pages | 2 |
| Journal | Mayo Clinic proceedings |
| Volume | 94 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2019 |
ASJC Scopus subject areas
- General Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Mayo Clinic proceedings, Vol. 94, No. 7, 07.2019, p. 1380-1381.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Improvement in Gastrointestinal Symptoms From Light Chain Amyloidosis After Adalimumab Therapy
AU - Al Saleh, Abdullah S.
AU - Sidiqi, M. Hasib
AU - Gertz, Morie A.
N1 - Funding Information: Potential Competing Interests: Dr Gertz reports receiving personal fees from Ionis/Akcea, Alnylam, Prothena, Celgene, Janssen, Annexon, Apellis, Amgen, Medscape, Physicians Education Resource, and Research to Practice; grants and personal fees from Spectrum; personal fees for data safety monitoring board membership from Abbvie; speaker fees from Teva, Johnson & Johnson, Medscape, and DAVA Oncology. He serves on the advisory board of Pharmacyclics and Proclara (outside the submitted work). He also reports receiving fees for participation in review activities from Abbvie; grant funding from Amyloidosis Foundation and International Waldenstrom's Macroglobulinemia Foundation; book royalties from Mayo Clinic Press; and payment for development of educational presentations from Medscape (all outside the submitted work). The other authors report no competing interests. Potential Competing Interests: Dr Gertz reports receiving personal fees from Ionis/Akcea, Alnylam, Prothena, Celgene, Janssen, Annexon, Apellis, Amgen, Medscape, Physicians Education Resource, and Research to Practice; grants and personal fees from Spectrum; personal fees for data safety monitoring board membership from Abbvie; speaker fees from Teva, Johnson & Johnson, Medscape, and DAVA Oncology. He serves on the advisory board of Pharmacyclics and Proclara (outside the submitted work). He also reports receiving fees for participation in review activities from Abbvie; grant funding from Amyloidosis Foundation and International Waldenstrom's Macroglobulinemia Foundation; book royalties from Mayo Clinic Press; and payment for development of educational presentations from Medscape (all outside the submitted work). The other authors report no competing interests.
PY - 2019/7
Y1 - 2019/7
UR - http://www.scopus.com/inward/record.url?scp=85067548939&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067548939&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2019.04.023
DO - 10.1016/j.mayocp.2019.04.023
M3 - Letter
C2 - 31272581
AN - SCOPUS:85067548939
SN - 0025-6196
VL - 94
SP - 1380
EP - 1381
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 7
ER -